Peter Hong

Peter Hong

Company: LG Chem Life Sciences Innovation Center, Inc.

Job title: President



Since becoming the President of LG Chem Life Sciences Innovation Center, Inc. in December 2021, Peter has provided strategic directions to advance key projects in clinical stage through setting clinical strategies and paving regulatory paths. Peter also leads initiatives to seek disruptive technologies and formulate actionable plans for the future growth areas with novel modalities.

From January 2019 to November 2021, Peter served as a Vice President and Head of Research at the headquarter of LG Chem Life Sciences Company in Seoul, South Korea. He led a group of 152 scientists who conceived new ideas, crystallized them into discovery projects, and advanced competitive projects into the development stage. Under his leadership, the R&D pipeline rapidly grew culminating 11 projects at IND-enabling stage, 6 projects entering Phase 1 trials, and 3 projects in Phase 2. Peter also spearheaded the initiatives of building in-house cell and gene therapy capabilities, which led up to allogeneic CAR-T cell therapy and iPSC-derived CAR-NK cell therapy planned to enter the clinic in 2023.

Prior to joining LG Chem Life Sciences Company, Peter worked for Regeneron Pharmaceuticals in Tarrytown, NY from December 2013. Peter made significant contributions to the development of life-changing therapies such as Praluent (PCSK9 inhibitor) for the treatment of familial hypercholestremia, Kevzara (IL-6R antagonist) for osteoarthritis, Dupixent (IL-4R/13R dual blocker) for atopic dermatitis, and Libtayo (PD-1 inhibitor) for various solid tumors. In addition, Peter was deeply involved in early research programs that engaged novel targets and platforms for immuno-oncology indications including bispecific antibody and CAR-T cells.

From July 2004 to November 2013, Peter held a range of leadership positions leading research collaborations with National Cancer Institute, Pacific Northwest National Laboratory, and Johns Hopkins University. Peter investigated detailed mechanisms of action for anticancer agents from small molecule kinase inhibitors and monoclonal antibodies.

Peter was born and raised in South Korea, earned BS/MS from School of Pharmacy at Seoul National University and PhD from College of Pharmacy at University of North Carolina Chapel Hill.

Location: Cambridge, Massachusetts, United States


For contact information, please email

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.